RDEA594 is a development candidate that has potential for treating gout patients with hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 studies with RDEA806 in healthy volunteers, increased urinary excretion of uric acid was observed in the first 24 hours after dosing, with statistically significant, exposure-dependent, decreases in serum uric acid of 35% to 50% observed following 10-14 days of dosing. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1-mediated uptake of uric acid ex vivo and is believed to be responsible for the uric acid-lowering effects of RDEA806. Approximately 90% of hyperuricemic patients are considered to be under-excretors of uric acid, so increasing excretion may provide the most physiologically appropriate treatment. RDEA594 does not have significant antiviral activity.
About Ardea Biosciences
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, cancer and inflammatory diseases,
including gout. We have four drug candidates in clinical trials and others
in preclinical development and discovery. Our most advanced development
candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), which is in a Phase 2a study for the treatment of HIV. We have
evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in
a human micro-dose pharmacokinetic study and have selected it as a
development candidate. RDEA594, our lead developme
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved